Opko Health, Inc. (OPK): Revenue
$606.88M
Year ended 2025-12-31
$587.90M
Trailing 12 months to 2026-06-30
-15.5%
3-year compound annual growth
-15.8%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $606.88M | -14.9% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $713.14M | -17.4% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $863.50M | -14.0% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $1.00B | -43.4% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $1.77B | +23.6% | 2024-03-01, From 2021-01-01 |
| 2020-12-31 | $1.44B | +59.1% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $901.93M | -8.9% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $990.27M | +2.5% | 2021-02-18, From 2018-01-01 |
| 2017-12-31 | $966.01M | -13.6% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $1.12B | n/a | 2019-03-01, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Opko Health, Inc. (OPK) | 2025-12-31 | $606.88M | -14.9% |
| Insmed Inc (INSM) | 2025-12-31 | $606.42M | +66.7% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $616.29M | +87.3% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $638.50M | +65.5% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $564.17M | +17.0% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $548.51M | -13.0% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $673.00M | +20.2% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $677.56M | +60.1% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $521.31M | +54.7% |
Compare OPK, INSM, TGTX, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗